Resource Summary Report

Generated by dkNET on Sep 1, 2026

BT-20

RRID:CVCL_0178
Type: Cell Line

Proper Citation

RRID:CVCL_0178

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0178

Proper Citation: RRID:CVCL_0178

Description: Cell line BT-20 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: PMID:833871, PMID:3518877, PMID:4831449, PMID:6220172, PMID:6582512, PMID:7017212, PMID:7459858, PMID:10969801, PMID:11414198, PMID:11789735, PMID:12661003, PMID:12800145, PMID:13611537, PMID:16397213, PMID:16541312, PMID:17157791, PMID:19582160, PMID:19593635, PMID:20164919, PMID:20215515, PMID:21778573, PMID:22460905, PMID:22585861, PMID:23151021, PMID:23601657, PMID:24094812, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25892236, PMID:25960936, PMID:25984343, PMID:26589293, PMID:27397505, PMID:28889351, PMID:30894373, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BT-20

Synonyms: BT 20, BT20

Cross References: BTO:BTO_0001466, CLO:CLO_0002041, EFO:EFO_0001092, MCCL:MCC:0000069, CLDB:cl493, CLDB:cl494, CLDB:cl495, ABM:T8959, AddexBio:C0006014/4910, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-7912, ATCC:HTB-19, BioSample:SAMN03471671, BioSample:SAMN03472738, BioSample:SAMN10987894, cancercelllines:CVCL_0178, CCRID:1101HUM-PUMC000335, Cell_Model_Passport:SIDM00893, ChEMBL-Cells:CHEMBL3307766, ChEMBL-Targets:CHEMBL613870, CLS:300130, Cosmic:687463, Cosmic:871137, Cosmic:904350, Cosmic:906801, Cosmic:934519, Cosmic:979719, Cosmic:991332, Cosmic:997914, Cosmic:1010923, Cosmic:1017159, Cosmic:1018465, Cosmic:1046932, Cosmic:1047701, Cosmic:1136370, Cosmic:1287931, Cosmic:1289382, Cosmic:1434946, Cosmic:1524352, Cosmic:1603190, Cosmic:1609471, Cosmic:1995348, Cosmic:2009507, Cosmic:2036672, Cosmic:2301232, Cosmic:2301522, Cosmic:2307195, Cosmic:2318378, Cosmic:2361352, Cosmic-CLP:906801, DepMap:ACH-000536, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906801, GEO:GSM184390, GEO:GSM184391, GEO:GSM350505, GEO:GSM421860, GEO:GSM459725, GEO:GSM783945, GEO:GSM827574, GEO:GSM843445, GEO:GSM843446, GEO:GSM847197, GEO:GSM847452, GEO:GSM886891, GEO:GSM887956, GEO:GSM1053689, GEO:GSM1172940, GEO:GSM1238127, GEO:GSM1374406, GEO:GSM1374407, GEO:GSM1401673, GEO:GSM1669629, IARC_TP53:3, IBRC:C10149, IGRhCellID:BT20, KCLB:60061, LiGeA:CCLE_451, LINCS_HMS:50105, LINCS_LDP:LCL-1476, Lonza:114, NCBI_Iran:C434, PharmacoDB:BT20_108_2019, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0178, PubChem_Cell_line:CVCL_0178, SLKBase:3481, TOKU-E:693, Wikidata:Q52392673

ID: CVCL_0178

Record Creation Time: 20220427T215414+0000

Record Last Update: 20260829T231646+0000

Ratings and Alerts

No rating or validation information has been found for BT-20.

Warning: Discontinued: ATCC; CRL-7912
Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 921 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Shi J, et al. (2026) TSPYL5 Promotes Triple-Negative Breast Cancer Metastasis by Antagonizing USP10-Mediated PTEN Stabilization to Unleash a ZEB1-Dependent EMT Program. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e20273.

Luo L, et al. (2026) CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. Nature communications, 17(1), 619.

Rosado-Sanz M, et al. (2026) Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. Oncoimmunology, 15(1), 2687381.

Karunaraj P, et al. (2026) A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance. Nature communications, 17(1).

Boušková V, et al. (2025) Integrative miRNOMe profiling reveals the miR-195-5p-CHEK1 axis and its impact on luminal breast cancer outcomes. Molecular oncology.

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. Cell reports. Medicine, 6(8), 102252.

Devlin KL, et al. (2025) Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. Cell reports, 45(1), 116826.

Nieto-Felipe J, et al. (2025) Notch1 regulates Orai1 and Orai3 expression in breast cancer cells. Scientific reports, 16(1), 3229.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Karunaraj P, et al. (2025) A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. bioRxiv : the preprint server for biology.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Karunaraj P, et al. (2025) A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. Research square.

Jeon JH, et al. (2025) Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer. Cancer & metabolism, 13(1), 42.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American

Association for Cancer Research, 31(7), 1275.

Minati R, et al. (2025) CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling. Cell reports, 44(12), 116676.

Lee CH, et al. (2025) MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer. Breast cancer research : BCR, 27(1), 136.

Kai J, et al. (2025) Building simplified cancer subtyping and prediction models with glycan gene signatures. Cell reports methods, 5(8), 101140.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell chemical biology.

Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(47), e11349.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.